Inhibition of Rho-Kinase by Fasudil Suppresses Formation and Progression of Experimental Abdominal Aortic Aneurysms

Chen Peng1, Peng Gu1*, Jing Zhou2, Jianhua Huang1, Wei Wang1*

1 Department of Vascular Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China, 2 Department of Stomatolog, Xiangya Hospital, Central South University, Changsha, Hunan, China

Abstract

Objective: Accumulating evidence suggests that inflammatory cell infiltration is crucial pathogenesis during the initiation and progression of abdominal aortic aneurysm (AAA). Given Rho-kinase (ROCK), an important kinase control the actin cytoskeleton, regulates the inflammatory cell infiltration, thus, we investigate the possibility and mechanism of preventing experimental AAA progression via targeting ROCK in mice porcine pancreatic elastase (PPE) model.

Methods and Results: AAA was created in 10-week-old male C57BL/6 mice by transient intraluminal porcine pancreatic elastase infusion into the infrarenal aorta. The mRNA level of RhoA, RhoC, ROCK1 and ROCK2 were elevated in aneurismal aorta. Next, PPE infusion mice were orally administered with vehicle or ROCK inhibitor (Fasudil at dose of 200 mg/kg/day) during the period of day 1 prior to PPE infusion to day 14 after PPE infusion. PPE-infusion mice treated with Fasudil produced significantly smaller aneurysms as compare to PPE infusion mice treated with vehicle. AAAs developed in all vehicle-treated groups within 14 days, whereas AAAs developed in six mice (66%, 6/9) treated with Fasudil within 14 days. Furthermore, our semi-quantitative histological analysis revealed that blood vessels and macrophages were significantly reduced in Fasudil treated mice during the AAA progression. Finally, when mice with existing AAAs were treated with Fasudil, the enlargement was nearly completely suppressed.

Conclusion: Fasudil inhibits experimental AAA progression and stabilize existing aneurysms, through mechanisms likely related to impaired mural macrophage infiltration and angiogenesis. These findings suggest that ROCK inhibitor may hold substantial translational value for AAA diseases.

Citation: Peng C, Gu P, Zhou J, Huang J, Wang W (2013) Inhibition of Rho-Kinase by Fasudil Suppresses Formation and Progression of Experimental Abdominal Aortic Aneurysms. PLoS ONE 8(11): e80145. doi:10.1371/journal.pone.0080145

Editor: Qingbo Xu, King’s College London, University of London, United Kingdom

Received August 31, 2013; Accepted October 10, 2013; Published November 14, 2013

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: wangweicui@gmail.com

Introduction

Abdominal aortic aneurysm (AAA) is a common degenerative disease of the abdominal aorta that leads to its dilatation and to rupture. The mortality of ruptured AAA approximates 90% [1]. Surgical repair is considered appropriate when the aortic diameter exceeds 55 mm [2]. However, an effective therapeutic strategy for small AAA is not available. Especially, to date, no pharmacology strategy has proven effective in limiting aneurysm progression or reducing risk of rupture [3,4].

AAA is characterized by atherosclerotic changes with chronic inflammation of aortic walls where increased infiltration of inflammatory cells into the vascular wall. Monocytes and macrophages are a major source of proteases that attack the structural integrity of the vascular wall and degrade components of the extracellular matrix, including elastin and collagen, thus contributing to AAA formation [5,6,7]. Whereas angiogenesis, a prominent pathological phenomena in the media and adventitia of aneurismal aorta suggests that angiogenesis may potentially contribute to the development and progression of AAA disease [8,9,10]. Given the crucial role of macrophages and angiogenesis in AAA pathogenesis, targeting pathways that influence macrophage infiltration and angiogenesis within aortae may provide an attractive alternative for medical disease management.

The Rho-proteins control an incredibly diverse array of cellular processes, including cytoskeletal dynamics, cell polarity, membrane transport, gene expression, cell proliferation, apoptosis and transcription factor activity. Our previous studies focus on the effect of Rho-protein on the tumor cells [11,12,13,14,15]. Actually, Accumulating evidence suggests that Rho-protein takes critical role in process of macrophage infiltration and angiogenesis [16,17,18,19,20,21]. Rho kinase (ROCK) is a major downstream effector of the small GTPase RhoA. ROCK family, consisting of ROCK1 and ROCK2, plays central role in the organization of actin cytoskeleton and is involved in a wide range of fundamental cellular functions such as contraction, adhesion, migration, proliferation, and apoptosis. Importantly, recent studies showed that Rho GTPase/RhoA pathway and its downstream effectors,
Moreover, fasudil, a selective ROCK inhibitor, has been used in the clinical trials of several cardiovascular diseases [27,28]. In fact, beneficial effects obtained in Apolipoprotein E-deficient mice with Rho-kinase inhibitor (fasudil) in experimental AAA have been confirmed [29]. However, there was obviously pathological difference between Apolipoprotein E-deficient mice AAA model and porcine pancreatic elastase (PPE) infusion mice AAA mode [30,31]. To date, the significance of Rho-kinase inhibitor in PPE infusion mice AAA mode remains unknown. Therefore, to investigate the possibility of preventing AAA progression in PPE mode via targeting RhoA/ROCK pathway is anticipated.

Here, Fasudil, a selective ROCK inhibitor was employed to investigate the effects of systemically inhibition of ROCK in experimental AAA. Furthermore, the mechanism of Fasudil suppress AAA progression was determined. Especially, to evaluate the clinical value of Fasudil, we investigate the inhibitory effect of Fasudil for existing aneurysm in experimental AAA. Our study suggests that ROCK inhibitor may have translational potential for clinical AAA disease management.

Methods

Mice and Ethics Statement

All experiments were performed in 10-week-old male C57BL/6 mice (Central Animal Care Unit, Central South University, Changsha, China). Experimental procedures and care for laboratory animals were approved by the Administrative Panel on Laboratory Animal Care at Xiangya hospital, Central South University. The Fasudil was purchased from LC Laboratories (Woburn, MA. Cat. F-4660). Antibodies against CD31 and CD68 were purchased from Biolegend (San Diego, CA).

Experimental aneurysm creation and diameter determination

AAA was created via intra-aortic PPE infusion as previously described [30,32,33,34,35,36]. Briefly, under inhaled anesthesia (2% isoflurane), the infrarenal abdominal aorta was isolated from the level of the left renal vein to the iliac bifurcation via median laparotomy, and temporarily controlled proximally and distally with 6-0 silk suture under operative magnification. Heat-tapered tubing was inserted into the controlled aortic segment just above the bifurcation. PPE was infused for 5 min into this region (30 μL...
of 1.5 U/mL type I PPE in saline, cat.# E1250, Sigma-Aldrich, St. Louis, MO). Following infusion and aspiration of residual infusate, the tubing was withdrawn and the aortotomy closed with a 10-0 nylon suture. AAA was defined by aortic diameters increase more than 50% over baseline levels. The formation and progression of AAAs were monitored by serial transabdominal aortic diameter ultrasound measurements (SonoSite, Fujifilm, Japan) prior to PPE infusion (day 0), and 3, 7, and 14 days after PPE infusion as previously described. All diameter measurements were performed by two single investigators blinded to study group assignment.

**Fasudil treatment**

Fasudil was diluted in 0.9% normal saline vehicle solution. 200 mg/kg/day for Fasudil was administrated by oral gavages thrice daily with an animal needle [29], or an equivalent volume

---

**Figure 3. Fasudil treatment attenuates the inflammatory cell infiltration in AAAs** Histological staining of EVG, SMC, CD31+ blood vessels and CD68+ macrophages were performed to evaluate the development of AAAs. Aortic sections were stained with Elastin Masson Stain for elastin fibers or immunostained with antibody against SMC a-actin for SMCs, antibody against CD31 for blood vessels and antibody against CD68 for macrophages. (A): Representative aortic histology images for elastin, SMCs, MVD and macrophages in each group. Original magnification: x200. (B&C): Elastic fragmentation and SMCs destruction were scored as mild 1 to severe 5 using a histology grading system. (D&E): CD31+ blood vessels and CD68+ macrophages in media and adventitia were counted on each ACS, and data present as Mean and SD per ACS. n = 7–9 in each group. Nonparametric Mann-Whitney test. * P<0.05 vs vehicle group.

doi:10.1371/journal.pone.0080145.g003
Figure 4. Fasudil treatment in existing aneurysm. Mice were treated orally with vehicle or Fasudil thrice daily at dose of 200 mg/kg/day during the period of day 4 to day 14 after PPE infusion. Changes in aortic diameter were measured on day 3 and 10 after Fasudil treatment. (A): Representative ultrasound images of aorta from PPE-infused mice treated with vehicle or Fasudil. (B): Mean and SD of aortic diameters changes after vehicle or Fasudil treatment. Nonparametric Mann-Whitney test, n = 7–9 mice in each group. * P<0.05. (C): Aortic sections were stained with Elastin Masson stain or with an antibody against SMC a-actin, CD31 and CD68 respectively, representative images of tissue immunostaining have been provided.
vehicle solution from starting 1 day prior to AAA creation for 15 days, or starting 4 days after AAA creation for 9 days.

**Real-Time Quantitative PCR**

Total RNA was isolated by using TRIzol reagent (Invitrogen) followed by DNase (Invitrogen) treatment according to the manufacturers’ instructions. Two microgram of total RNA was reverse transcribed into cDNA with M-MLV reverse transcriptase. Real-time PCR involved SYBR-green dye and Taq polymerase were performed on ABI 7900HT Real-Time PCR machine. The primer sequences were as following: RhoA: Forward Primer 5’-AGCTTTGTTGGAAGAGAGTTGG-3’; Reverse Primer 5’-GTTCCCAATAAGCGCAACTCTAC-3’; RhoB: Forward Primer 5’-GTGCCATTGATCGTGTCTCA-3’; Reverse Primer 5’-GTTCGCCACATATGTCTCTGAA-3’; RhoC: Forward Primer 5’-ATGGCTGCGATCCGAAAGAAG-3’; Reverse Primer 5’-GCACGTGACTCCCTGGAAACT-3’; ROCK1: Forward Primer 5’-GACGTGGGAGACGGTTTAGAGAC-3’; Reverse Primer 5’-GGGAGATCGCAATCCATCCAGC-3’; ROCK2: Forward Primer 5’-TTGGCTTCTGATCAAGGCACTGAC-3’; Reverse Primer 5’-GTGGTCGAAAGGCCGATAATATCT-3’; GAPDH: Forward: 5’-ACCACAGTCCATTGACATCC-3’, Reverse:5’-TCCACCACCATGGTGCTTA-3’; The fold change in expression of each target mRNA relative to GAPDH was calculated based on the threshold cycle as \( 2^{-\Delta\Delta Ct} \), where \( \Delta Ct = Ct_{\text{target}} - Ct_{\text{GAPDH}} \) and \( \Delta\Delta Ct = \Delta Ct_{\text{treatment}} - \Delta Ct_{\text{control}} \). The mRNA expression of each gene in aorto in Sham-operated mice as compare to control mice (P<0.05). Furthermore, the Rho-kinase (ROCK1 and ROCK2), the major target pathway of RhoA, were also investigated in aneurismatic and control mice. Anticipatively, an increased expression of ROCK1 and ROCK2 were observed (Fig. 1). These results suggested that Rho-GTPase and Rho-kinase were elevated in aorta from aneurismatic mice.

**Orally administration of Fasudil, a ROCK inhibitor, inhibits AAA formation and progression**

Based on the increased expression of Rho-GTPase and Rho-kinase in aneurismatic aorta, we hypothesize that Rho-kinase inhibitor treatment could influence the AAA formation and progression. Here, Male C57BL/6 mice were orally administrated with vehicle or ROCK inhibitor (Fasudil at dose of 200 mg/kg/day) during the period of day 1 prior to PPE infusion to day 14 after PPE infusion. PPE infusion mice treated with Fasudil produced significantly smaller aneurysms as compare to PPE infusion mice treated with vehicle. In every time point of aneurysm progression (3, 7 and 14 day), Mean aortic diameters after PPE infusion in Fasudil treatment group was significantly smaller than PPE infusion in vehicle treatment group (Fig. 2A&B). AAs developed in all vehicle-treated groups within 14 days, whereas AAA developed in six mice (66%, 6/9) treated with Fasudil within 14 days (Fig. 2C). Together, these results indicated that Fasudil treatment inhibits experimental AAA formation and progression.

**Fasudil treatment attenuates the inflammatory cell infiltration in AAA**

To further confirm the inhibition of Fasudil for experimental AAA, Elastic-Massion staining and SMC immunostaining on aortic sections were performed. As showed in Fig. 3A-C, mice in vehicle-treated group present severely reduced medial elastin density and SMC cellularity, whereas both elastin fragmentation and SMC depletion were significantly attenuated in Fasudil treated mice. Together, these results indicated that ROCK inhibitor treatment inhibits experimental AAA formation and progression. Next, to investigate the mechanism by which Fasudil modify aneurysm pathogenesis, tissue immunostaining was used to evaluate the presence and magnitudes of inflammatory cell infiltration. Our semi-quantitative histological analysis revealed that blood vessels and macrophages cells infiltration were significantly reduced in Fasudil treated mice (Fig. 3A,D,E). This result indicated that Fasudil inhibits AAA progression through preventing inflammatory cell infiltration.

**Fasudil treatment stabilizes existing aneurysm.**

To evaluate the translational value of Fasudil mediated AAA suppression, mice were treated orally with vehicle or Fasudil at dose of 200 mg/kg/day during the period of day 4 to day 14 after PPE infusion. As shown in Fig. 4A&B, aortic diameter in PPE-infusion, vehicle-treated mice continued to enlarger during this timeframe. Whereas enlargement was suppressed in PPE-infusion mice treated with Fasudil, especially in day 3 after Fasudil treatment, enlargement was nearly completely suppressed. Consistent with the previous results, mural macrophage and neovessel density were also significantly reduced in delayed-treatment as compared to those in vehicle-treated mice (Fig. 4C-F). These results indicate that Fasudil treatment stabilizes existing aneurysm by preventing mural inflammatory cell infiltration.
Discussion

Our results demonstrated that the formation and progression of experimental AAA in PPE infusion mice were reduced by Fasudil. The data further demonstrated that Fasudil treatment stabilizes existing aneurysm, which highlights the translational value of Fasudil for AAA management in clinical.

Chronic inflammation of aortic walls is the major pathogenesis in AAA progression. During this process, increased macrophages infiltrated into the vascular wall and degrade components of the extracellular matrix, including elastin and collagen, resulted in AAA formation [5,6,7]. RhoGTase, including RhoA, RhoB and RhoC, have been described as "molecular switches" and play a role in cell proliferation, apoptosis, gene expression, and multiple other common cellular functions [41,42]. Their downstream effectors, Rho kinases (ROCKs) are serine-threonine protein kinases that regulate the actin cytoskeleton. Recent studies suggest that RhoGTase and ROCKs play an important role in cardiovascular disease [43,44]. In present study, we firstly investigate the relative mRNA expression of RhoA, RhoB, RhoC, ROCK1 and ROCK2 in experimental AAA. Anticipatively, our result showed that RhoA, RhoC and ROCK were elevated in aneurismal mice, which indicated that potential important role of ROCK in progression of AAA.

Fasudil, a selective RhoA/Rho kinase (ROCK) inhibitor, has been used in clinical for the treatment of cerebral vasospasm and pulmonary hypertension [45]. Wang et al reported that administration of Fasudil to mice drinking water at a concentration of 1.0 mg/ml resulted in an average plasma concentration of hydroxyfasudil of 4 μmol/L and significantly attenuated Ang II-induced AAA [29]. In our study, PPE infusion mice were administrated with Fasudil at dose of 200 mg/kg/day by oral gavages thrice daily. Our results demonstrated that the incidence and progression of experimental AAA in PPE infusion mice were reduced by Fasudil. Because after oral administration, Fasudil metabolizes to a more selective and potent Rho-kinase inhibitor, hydroxyfasudil, which has been shown to inhibit Rho-kinase = 100- and 1000-fold more potently than protein kinase C and myosin light-chain kinase, respectively [46,47], thus, inhibition the progression of PPE infusion AAA after oral administration of Fasudil in our study is likely related to the specific inhibition of ROCK.

Vascular inflammation includes macrophage infiltration and angiogenesis. In the present study, our semi-quantitative histological analysis revealed that macrophages infiltration was significantly reduced in Fasudil treated mice. This result consists with the previous study that Rho-kinase mediates Ang II-induced macrophage migration, which can be inhibited by Fasudil [48,49]. Since many of the pro-inflammatoryatory genes are activated in human primary macrophages [50,51], decreased macrophage infiltration indicates a decreased inflammatory cytokine release, which prevent the progression of AAAs. In fact, previous study has suggested that Fasudil treatment can inhibit MMP activities and reduced apoptosis, in support of the assertion that ROCK inhibition strategies [52,53,54,55,56]. We treated orally the mice with Fasudil after PPE infusion and aneurysm has formatted. The results showed that vehicle-treated mice continued to enlarge, whereas enlargement was suppressed in PPE-infusion mice treated with Fasudil. Meanwhile, mural macrophage and neovessel density were also significantly reduced in delayed-treatment as compared to those in vehicle-treated mice. These results suggest an important clinical value for ROCK inhibitor.

Together, our experiment demonstrate the ability of the ROCK inhibitor to both suppress experimental AAA initiation and stabilize existing aneurysms, through mechanisms likely related to impair mural macrophage infiltration and angiogenesis. These findings suggest that ROCK inhibitor may hold substantial translational value for AAA diseases.

Author Contributions
Conceived and designed the experiments: WW JH. Performed the experiments: CP PG JZ. Analyzed the data: WW JZ. Contributed reagents/materials/analysis tools: WW JZ. Wrote the paper: WW JH.
10. Kroll J, Eping D, Kern K, Dietz CT, Feng Y, et al. (2009) Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis. Am J Physiol Heart Circ Physiol 296: H1893–99.

11. Mamamoto A, Mamamoto T, Inger DE (2008) Rho signaling and mechanical control of vascular development. Curr Opin Hematol 15: 228–234.

12. Bryan BA, D’Amore PA (2007) What tangled webs they weave: Rho-GTPase control of angiogenesis. Cell Mol Life Sci 64: 2053–2065.

13. Hyceln JM, Howell K, Nichol A, Costello CM, Preston RJ, et al. (2005) Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 97: 183–191.

14. He M, Cheng Y, Li W, Liu Q, Liu J, et al. (2010) Vascular endothelial growth factor-C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer 10: 170.

15. Bryan BA, Denuetche E, Mitchell DC, Walche TE, Noma K, et al. (2013) ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J 24: 3186–3195.

16. Croft DR, Sahai E, Mavria G, Li S, Tsai J, et al. (2004) Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Res 64: 9894–9901.

17. Shi J, Wei L (2013) Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol 62:341–354.

18. Liouat G, Guerin P, Faccia P (2006) Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98: 322–334.

19. Liu J, Yao GE, Zhou HD, Jiang XJ, Xie P (2013) Clinical Investigation of Fasudil for the Prevention of Cerebral Vasospasm in Extracranial Carotid Artery Stenting. Cell Biochem Biophys Jun 26. [Epub ahead of print].

20. Kaja SG (2012) Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension. Recent Pat Cardiovasc Drug Discov 7: 100–104.

21. Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, et al. (2005) Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation 111: 2219–2226.

22. Maegdefessel L, Azuma J, Toh R, Merk DR, Deng A, et al. (2012) Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest 122: 497–506.

23. Miyama N, Dua MM, Yeung JJ, Schultz GM, Asagami T, et al. (2010) Hyperglycemia limits experimental aortic aneurysm progression. J Vasc Surg 52: 975–983.

24. Tedesco MM, Terashima M, Blankenberg FG, Levashova Z, Spin JM, et al. (2009) Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol 29: 1452–1457.

25. Maegdefessel L, Azuma J, Toh R, Deng A, Merk DR, et al. (2012) MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med 4: 122ra122.

26. Leeper NJ, Raieddana A, Kojima Y, Kimb RW, Cheng H, et al. (2013) Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler Thromb Vasc Biol 33: e1–e10.

27. Iida Y, Xu B, Schultz GM, Chow V, White JJ, et al. (2012) Efficacy and mechanism of angiotension II receptor blocker treatment in experimental abdominal aortic aneurysms. PLoS One 7: e49642.

28. Iida Y, Xu B, Schultz GM, Chow V, White JJ, et al. (2012) Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 97: 183–191.

29. He M, Cheng Y, Li W, Liu Q, Liu J, et al. (2010) Vascular endothelial growth factor-C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer 10: 170.

30. Bryan BA, Denuetche E, Mitchell DC, Walche TE, Noma K, et al. (2013) ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J 24: 3186–3195.

31. Liu J, Yao GE, Zhou HD, Jiang XJ, Xie P (2013) Clinical Investigation of Fasudil for the Prevention of Cerebral Vasospasm in Extracranial Carotid Artery Stenting. Cell Biochem Biophys Jun 26. [Epub ahead of print].

32. Kaja SG (2012) Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension. Recent Pat Cardiovasc Drug Discov 7: 100–104.

33. Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, et al. (2005) Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation 111: 2219–2226.

34. Maegdefessel L, Azuma J, Toh R, Merk DR, Deng A, et al. (2012) Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest 122: 497–506.

35. Miyama N, Dua MM, Yeung JJ, Schultz GM, Asagami T, et al. (2010) Hyperglycemia limits experimental aortic aneurysm progression. J Vasc Surg 52: 975–983.

36. Tedesco MM, Terashima M, Blankenberg FG, Levashova Z, Spin JM, et al. (2009) Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol 29: 1452–1457.

37. Maegdefessel L, Azuma J, Toh R, Deng A, Merk DR, et al. (2012) MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med 4: 122ra122.

38. Leeper NJ, Raieddana A, Kojima Y, Kimb RW, Cheng H, et al. (2013) Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler Thromb Vasc Biol 33: e1–e10.

39. Iida Y, Xu B, Schultz GM, Chow V, White JJ, et al. (2012) Efficacy and mechanism of angiotension II receptor blocker treatment in experimental abdominal aortic aneurysms. PLoS One 7: e49642.